Open AccessThis article is
- freely available
Foamy Virus Vectors for HIV Gene Therapy
Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA
School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
* Author to whom correspondence should be addressed.
Received: 1 September 2013; in revised form: 10 October 2013 / Accepted: 16 October 2013 / Published: 22 October 2013
Abstract: Highly active antiretroviral therapy (HAART) has vastly improved outcomes for patients infected with HIV, yet it is a lifelong regimen that is expensive and has significant side effects. Retroviral gene therapy is a promising alternative treatment for HIV/AIDS; however, inefficient gene delivery to hematopoietic stem cells (HSCs) has so far limited the efficacy of this approach. Foamy virus (FV) vectors are derived from non-pathogenic viruses that are not endemic to the human population. FV vectors have been used to deliver HIV-inhibiting transgenes to human HSCs, and they have several advantages relative to other retroviral vectors. These include an attractive safety profile, broad tropism, a large transgene capacity, and the ability to persist in quiescent cells. In addition, the titers of FV vectors are not reduced by anti-HIV transgenes that affect the production of lentivirus (LV) vectors. Thus FV vectors are very promising for anti-HIV gene therapy. This review covers the advantages of FV vectors and describes their preclinical development for anti-HIV gene therapy.
Keywords: foamy virus; lentivirus; retrovirus; vector; gene therapy; HIV
Citations to this Article
Cite This Article
MDPI and ACS Style
Olszko, M.E.; Trobridge, G.D. Foamy Virus Vectors for HIV Gene Therapy. Viruses 2013, 5, 2585-2600.
Olszko ME, Trobridge GD. Foamy Virus Vectors for HIV Gene Therapy. Viruses. 2013; 5(10):2585-2600.
Olszko, Miles E.; Trobridge, Grant D. 2013. "Foamy Virus Vectors for HIV Gene Therapy." Viruses 5, no. 10: 2585-2600.